Foamy viral envelope genes
AssigneeVectoria Forschungsforderungs Verein E.V.
InventorsDirk Lindemann, Kristin Stirnnagel, Daniel Lueftenegger
Life of this patent
Estimating the term…
Abstract
The present invention concerns the technical field of nucleic acids and expression-optimized nucleic acids. The present invention concerns especially nucleic acids comprising a mutated foamy viral envelope gene encoding a foamy viral envelope polypeptide, which comprises a leader peptide (LP), a surface unit (SU) and a transmembrane domain (TM). The present invention also relates to modified polypeptides encoded by these nucleic acids. Furthermore, the present invention regards a method for preparing pseudotyped vector particles as well as a method for treating a genetic disorder comprising administering a nucleic acid or a polypeptide encoded by that nucleic acid.
Claims16
A nucleic acid comprising a foamy viral envelope gene encoding a modified foamy viral envelope polypeptide comprising a leader peptide (LP), a surface unit (SU) and a transmembrane domain (TM), wherein the polypeptide has an N terminus,
- wherein the nucleic acid is expression-optimized,
- wherein the nucleic acid encodes a modified foamy viral envelope gene comprising at least one mutation in a nucleic acid sequence encoding the LP, wherein the mutation results in inactivation of at least one ubiquitination site in the modified envelope polypeptide, and,
- wherein the foamy viral envelope gene comprises a sequence selected from the group consisting of SEQ ID NO:
- 7 (PE01), SEQ ID NO:
- 8 (PE02), SEQ ID NO:
- 9 (PE03), SEQ ID NO:
- 10 (SE01), SEQ ID NO:
- 11 (SE02) and SEQ ID NO:
- 12 (SE03).
A nucleic acid comprising a foamy viral envelope gene encoding a modified foamy viral envelope polypeptide comprising a leader peptide (LP), a surface unit (SU) and a transmembrane domain (TM), wherein the polypeptide has an N terminus,
- wherein the nucleic acid is expression-optimized,
- wherein the nucleic acid encodes a modified foamy viral envelope gene comprising at least one mutation in a nucleic acid sequence encoding the LP, wherein the mutation results in inactivation of at least one ubiquitination site in the modified envelope polypeptide, wherein the modified envelope polypeptide pseudotypes a viral vector for infecting at least one host cell, wherein infectivity of the pseudotyped viral vector is increased by expression-optimization up to about 50-fold compared to a non-optimized nucleic acid encoding the same modified envelope polypeptide, and,
- wherein the foamy viral envelope gene comprises a sequence selected from the group consisting of SEQ ID NO:
- 7 (PE01), SEQ ID NO:
- 8 (PE02), SEQ ID NO:
- 9 (PE03), SEQ ID NO:
- 10 (SE01), SEQ ID NO:
- 11 (SE02) and SEQ ID NO:
- 12 (SE03).
Dependencies are inferred from the claim text.